MPR1d
Low-Dose Atropine Eye Drops Under Review for Pediatric Myopia
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...
Ophthalmology Times4d
FDA accepts new drug application for low-dose atropine from Sydnexis
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
Healio4d
FDA accepts new drug application for SYD-101 to treat pediatric myopia progression
The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...
Myopia is a disease, not a refractive error — here’s what that means
In December, the U.S.-based National Academy of Sciences published a report classifying myopia, for the first time, as a ...
Association of Optometrists (AOP)4d
From a summer birth to high intelligence: unravelling myopia risk
Paediatric ophthalmologist, Dr Katie Williams, discusses her research exploring factors associated with myopia ...
Our children are rapidly losing their sight. What can be done?
Every morning – shortly after checking my phone and shortly before brushing my teeth – I pull down my lower eyelids in turn ...
Business Wire5d
Sydnexis Announces FDA Acceptance of New Drug Application for SYD-101 for the Treatment of Progression of Pediatric Myopia
Myopia is the most common eye disease in children ... pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the ...